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Abstract 35 
 36 
Objectives: To assess the biofilm reduction and discoloration potential of a new 37 
0.05% chlorhexidine (CHX) digluconate solution, containing additional essential oil 38 
and alcohol components (Parodentosan®), as compared to two control CHX 39 
solutions (0.05% CHX and 0.2% CHX) and water.  40 
Methods: The potential to reduce total viable counts of growing mixed microbial 41 
populations was examined using the Zurich biofilm model. Biofilms were created on 42 
sterile pellicle-coated hydroxyapatite discs and were exposed to test substances at 43 
different time points. After 64.5 h, mean CFU (colony forming units) and standard 44 
deviations were determined. Color change measurements using light reflection 45 
analysis were carried out on saliva pre-conditioned bovine dentin and enamel 46 
samples, as well as composite and a glass ceramic restorative materials, after 47 
successive immersions in a standardized tea brew and the CHX solutions. 48 
Results: Parodentosan was able to reduce biofilm formation by 3 log steps as 49 
compared to the water control. This was significantly less effective than the control 50 
CHX solutions, which were able to reduce viable counts by 6 log steps. Both 51 
Parodentosan and the control rinses exhibited staining on all surfaces. Staining was 52 
most pronounced on dentin, followed by enamel and to a significantly lesser degree 53 
on the restorative materials. The staining caused by Parodentosan was generally 54 
lower than by the control solutions on the restorative materials.  55 
Conclusions: Parodentosan exhibited an antimicrobial activity. The composition, 56 
however, seems to hamper its effectiveness. Accordingly, it produced statistically 57 
significant, though by trend less, staining on restorative materials.  58 
 (243 words) 59 
 60 
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 67 
Introduction 68 
 69 
   Various species of bacteria found in mature dental biofilms are recognized contributing 70 
factors to both periodontal diseases and caries development (1, 2). It has been shown that 71 
meticulous daily plaque control will prevent disease initiation, stop progression of the disease 72 
process, and combined with professional debridement, allow surrounding tissues to return to a 73 
healthy state (3-5). Unfortunately, inadequate daily removal of bacterial plaque and biofilm is 74 
widespread (6-8). Even well trained patients may miss hard-to-reach areas around posterior 75 
teeth or marginal gingiva. Additionally, people with malpositioned teeth, bridgework or 76 
orthodontic appliances and especially elderly people with physical or mental limitations may 77 
find brushing and interdental cleaning extremely difficult (9). Antimicrobial rinses are 78 
therefore often recommended as an adjunctive homecare procedure. Of all antimicrobials 79 
studied and currently used, chlorhexidine (CHX) has long been recognized as being the most 80 
effective for inhibiting plaque, preventing gingivitis and displaying a well-documented anti-81 
caries effect (10-13). In repeated studies, depending upon the concentration used, 82 
chlorhexidine has been shown to prevent plaque accumulation, with two marked negative side 83 
effects: surface staining and altered taste perception (14). Both side effects are reversible upon 84 
discontinuation of use, but remain a major stumbling block in regard to patient compliance. 85 
   Researchers, and industry, have placed a lot of effort in developing formulations that reduce 86 
the negative side effects while maintaining the powerful antimicrobial effect of chlorhexidine. 87 
However, due to the strong positive charge, CHX looses its antimicrobial effect rapidly when 88 
combined with organic or un-organic molecules (15, 16). Only lower concentrations appear to 89 
cause less stain, or less rapid staining, but at the cost of efficacy (17-19).  90 
   This study was designed and executed in two-parts, to determine first the antimicrobial 91 
efficacy of a new 0.05% chlorhexidine digluconate solution containing essential oil and 92 
alcohol components (Parodentosan®, Tetan AG, Ramlinsburg, Switzerland) and then assess 93 
its staining potential compared to control solutions. The null hypothesis tested was that the 94 
test product I) is as effective in reducing biofilm formation as the control solutions and II) that 95 
that it will cause identical staining as control solutions on enamel, dentin and selected 96 
restorative materials.  97 
 98 
 99 
 100 
 101 
Study population and methodology 102 
 103 
Antimicrobial solutions  104 
   The solutions tested in this experiment are listed in Table 1. Parodentosan is readily 105 
available over the counter in Switzerland.  The positive control chlorhexidine solutions were 106 
prepared in-house to ensure purity.  Deionized water was used as a negative control. 107 
 108 
Experiment 1: Biofilm formation  109 
 110 
Biofilms  111 
   Biofilms contained Actinomyces naeslundii OMZ 745, Veillonella  dispar OMZ 493, 112 
Fusobacterium nucleatum OMZ 596, Streptococcus sobrinus OMZ 176, and Streptococcus 113 
oralis OMZ 607 and C. albicans OMZ 110. Pellicle-coated hydroxyapatite discs (Ø 10.6 mm) 114 
in 24-well polystyrene cell culture plates were covered with 1.6 ml of processed whole 115 
unstimulated saliva + modified fluid universal medium (mFUM), supplemented with 67 116 
mmol/l Sørensen’s buffer (38% v/v), final pH 7.2) containing carbohydrate (20). The 117 
carbohydrate concentration in stock solutions of mFUM was 0.3% (w/v) and consisted of 118 
either glucose (biofilm cultivation from 0 to 16.5 h) or a 1:1 (w/w) mixture of glucose and 119 
sucrose (biofilm cultivation from 16.5 to 64.5 h). Wells were inoculated with mixed cell 120 
suspensions (200  µL) prepared from equal volumes of each species adjusted to an OD 550 121 
and incubated anaerobically at 37° C. Medium was changed after dipping (see below) at 16.5 122 
and 40.5 h by aspirating spent medium and adding back fresh medium (21). 123 
 124 
Evaluation of Antimicrobial Activities of Test Solutions  125 
   Biofilm-covered discs were immersed for 1 min in 1 ml of test solution, and then rinsed 126 
gently by dipping in physiological saline (3 x 2 ml). Biofilms were exposed to test substances 127 
at 16.5, 20.5, 24.5, 40.5, 44.5 and 48.5 h. After the last treatment biofilms were incubated 128 
undisturbed and harvested at 64.5 h by vigorous vortexing in physiological saline (1 ml). 129 
   Aliquots of harvested biofilm were sonified, diluted, and spiralplated onto Columbia agar 130 
base (Oxoid, Ltd., Basingstoke, Hamps., UK) containing 5% (v/v) haemolysed human blood 131 
(CBA) and incubated anaerobically at 37° C. Colony-forming units (CFUs) were counted 72 h 132 
after plating with the aid of a stereomicroscope.  133 
 134 
Statistics 135 
   Statistical analyses of the effects of different treatments on total biofilm populations were 136 
performed using log10-transformed total CBA CFUs. Skew distributions of the values 137 
measured for most products and different variances of the solutions examined required non-138 
parametrical statistical tests. Overall statistical analyses within defined groups of products 139 
were performed using the Kruskal-Wallis procedure as implemented in the program StatView 140 
II (Abacus Concepts, Inc., Berkeley CA, USA). Due to the multiple test situation, 141 
Bonferroni’s correction was applied. Results are presented as boxplots. 142 
 143 
Experiment 2: Staining potential 144 
 145 
Stain formation 146 
   A standardized in vitro method for reproducing stain in the presence of CHX was followed 147 
(22). A standard tea solution (Marks and Spencer extra strong, London, UK) was prepared by 148 
boiling 8g in 800 ml of distilled water for 2 minutes.  The solution was allowed to cool in a 149 
refrigerator at 4°C for 30 minutes and the infusion filtered through gauze to remove the 150 
tealeaves. Finally the tea solution was kept at 37°C during the experiment.  151 
   As test specimens, this investigation used different tooth and restorative materials (Table 2), 152 
in place of clear acrylic blocks. These specimens were prepared as follows: the crowns from 153 
sixty-four caries-free bovine mandibular incisors of two and a half year old animals were 154 
mechanically separated, the labial aspects sectioned (enamel n=32), and the middle dentine 155 
(n=32) prepared using a PD-Max grinder (Streuers GmbH, Birmensdorf, Switzerland) at 300 156 
revolutions per minute, under water cooling with SiC paper 500 grit (Merck, Dietikon, 157 
Switzerland) followed by p1000 grit (DIN 69176; grit size 18  µm) wet and polished by hand 158 
to a standardized reproducible flat surface [ISO/TR 1994]. The restorative materials were 159 
prepared by placing each material (n=32/material) in 13 mm round, 3 mm thick Teflon forms. 160 
In a first curing phase, the forms were only half filled and cured with a UV light source (blue 161 
phase, Ivoclar, Schaan, Liechtenstein) on 4 points within the circle radius for a total of 40 162 
seconds.  A second curing phase was performed after the forms were fully filled, on 6 points, 163 
for a total of 60 seconds. The specimens were then placed in a broad beam light-curing 164 
chamber (Spectramat, Ivoclar, Schaan, Liechtenstein) and cured for a third time, for 5 165 
minutes.  166 
   All specimens were embedded in optically clear epoxy resin (Stycast®, Emerson & 167 
Cuming, Waterlo, Belgium), which was mixed in the proportion Stycast 1266 Part A 15 g, 168 
Part B 4.2 g, 90 s by hand then 19 min under a vacuum pump to generate a bubble-free mass. 169 
The outer dimensions of the samples measured 20 mm in diameter, to fit the optical lens of a 170 
Konica/Minolta spectrophotometer (CM-508d, Konica Minolta Photo Imaging (Schweiz) AG, 171 
Switzerland).  172 
   The 5 specimen materials were divided into 4 groups of 8 specimens each. They were 173 
covered and bathed in a pooled stimulated human saliva (gathered from volunteers at 7.45 and 174 
11.45 on the day of testing, with no food having been ingested for at least 2 hours previously 175 
and held between cycles at 37°C) for 2 min at 37°C, then rinsed 4 times consecutively with 2 176 
ml deionised water. Each eight specimens were then covered and bathed by groups in one of 177 
the three CHX solutions applied in this experiment (Table 1) or with a deionised water 178 
negative control at 37°C for another 2 min, before being rinsed again 4 times consecutively 179 
with 2 ml deionised water. The specimens were then covered and bathed in the standard tea 180 
solution and reincubated for 1 h at 37°C. A final rinse of 4 consecutive 2ml washes was 181 
performed and the specimens were dried with compressed air and measured for luminosity 182 
using the CIELAB (L*a*b*) color system on a daylight, D65/10°, scale. The saliva/CHX/tea 183 
bath cycle was repeated 6 times over 11 hours. 184 
 185 
Stain determination 186 
   A baseline L*a*b* reading had been taken prior to the start of the saliva/chlorhexidine/tea 187 
baths and the changes in L* (luminosity), a* (red-green axis) and b* (yellow-blue axis) were 188 
recorded by a Konica/Minolta spectrophotometer (CM-508d, wavelength range 400-189 
700nm) and fed directly into a computer (MacIntosh G4, Apple, Cupertino, CA, USA).   190 
The overall color difference was calculated as: 191 
 ΔE*ab = [(ΔL*)2 + (Δa*)2 + (Δb*)2]1/2 192 
where ΔL* = L* interval - L* baseline ; Δa* = a* interval - a* baseline;  193 
Δb* = b* interval - b* baseline 194 
 195 
Statistics 196 
   Two-way analysis of variance (ANOVA) was used to compare differences in color upon the 197 
various substrate materials and under the influence of the 3 different chlorhexidine solutions 198 
and deionized water control.  Means were compared with Scheffe’s multiple comparison test 199 
at the 0.05 level of significance (StatView, Abacus Concepts, Inc., Berkley CA, USA). 200 
 201 
 202 
Results 203 
Experiment 1 204 
   The results of the biofilm experiment are graphically depicted in Figure 1.  205 
   The water control showed the highest number of viable microorganisms (1.5x108 ± 206 
5.3x107). Parodentosan was able to reduce the biofilm growth by 3 log steps (6.4x105 ± 207 
1.1x106; p < 0.05). The CHX control solutions showed almost complete inhibition of bacterial 208 
growth, i.e. a reduction of 6 and 7 log steps respectively. 209 
 210 
Experiment 2 211 
   The results are summarized in Table 3.  212 
   All substrate surfaces tended to become darker and more discolored over time. This 213 
darkening (ΔL*) and discoloration (ΔE*) was significantly more pronounced on the enamel 214 
and dentin samples, as compared to the 3 restorative materials. While contact with the test 215 
solutions did not produced significantly more staining than contact with water before the tea 216 
bath on either the enamel or dentin specimens, the change in luminosity (ΔL*) caused by the 217 
0.05% CHX solution was significantly higher than either the 0.2% CHX solution or 218 
Parodentosan. For the dentin samples, the color change along the red/green axis (Δa*) was 219 
significantly greater for both pure CHX solutions than the change displayed by Paradentosan.  220 
However, there were no significant changes in luminosity or overall color (ΔE*) for these 221 
dentin substrate samples, when compared to those caused by the water control. 222 
   On the micro-filler and ceramic substrates, the level of darkening (ΔL*) was significantly 223 
greater after contact with the pure CHX solutions, as compared to water or Parodentosan. 224 
However, all 3 CHX solutions produced a level of staining significantly higher than the water 225 
control on the nano-filler, with Parodentosan showing a tendency, though not statistically 226 
significant, for lesser staining also on this substrate.  227 
   On the nano-filler and ceramic specimens, significant shifts in overall color change (ΔE*) 228 
occured after exposure to both the additive and pure CHS solutions.  Again, Parodentosan 229 
displayed a tendency, though not statistically significant, for less staining.  However, on the 230 
micro-filler substrate, staining was significant for those specimens exposed to the pure CHX 231 
solutions, while Parodentosan only displayed a statistically insignificant difference to that 232 
recorded by the specimens exposed to the water control.  233 
Discussion 234 
   This study assessed the capability of a new 0.05% chlorhexidine digluconate solution 235 
containing essential oil (EO) and alcohol components to inhibit biofilm formation, as well as 236 
to determine its staining potential as compared to standard solutions.  237 
   It was found that the test solution had a significant antibacterial effect on the experimental 238 
biofilm, however a better efficiency with pure CHX solutions with or without equimolar 239 
alcohol content was observed. The latter solutions almost completely prevented biofilm 240 
formation and reduced the biofilm growth by 6 to 7 log steps. Therefore, the first null 241 
hypothesis was rejected.  242 
   As compared to data of a previous study applying the same methodology, the efficiency of 243 
the test product can be compared to Listerine® (Johnson & Johnson Healthcare Products, 244 
Skillman, NJ, USA), which contains menthol, thymol, methyl salicylate, and eucalyptol (23). 245 
Paradentosan and Listerine both reduce biofilm formation by 3 log steps. In Listerine, ethanol 246 
is present in concentrations of 21.6% in the flavored products and 26.9% in the original 247 
antiseptic formulation. Parodontosan contains 15 volume percent. 248 
   For the biofilm formation, hydroxyapatite discs were chosen to simulate the enamel 249 
structure. A previous study assessed biofilm growth on other substrates, i.e. human enamel 250 
and different composite resin materials (24). That study showed that surface roughness 251 
influenced initial biofilm adherence during the initial adherence phase (20 minutes), but 252 
differences vanished following growth and maturation (16.5 h).  253 
   The staining experiment showed that test and control rinses exhibited staining on all 254 
surfaces. Staining was most pronounced on dentin, followed by enamel and to a significantly 255 
lesser degree on restorative materials. The staining caused by the 0.05% CHX rinse 256 
containing EO was generally lower than the control CHX solutions on the restorative 257 
materials. In terms of the materials selected in this experiment, substrates relevant for the oral 258 
environment under clinical conditions, e.g. enamel, dentin, composite resin and ceramic 259 
material, were chosen.  260 
   Bovine enamel and dentin samples are commonly used as proxies for their human 261 
counterparts, as they are readily attainable in sufficient quantities for a study of this nature. 262 
The three restorative materials chosen for inclusion in this study were representative of their 263 
class: a micro filler hybrid, a nano filler hybrid, and a glass ceramic. All surfaces were 264 
polished with the same grit (P1000) to obtain comparable surfaces. As Stober et al. (2001) 265 
pointed out, this does not necessarily represent a clinical level of polishing, which might have 266 
reduced the level of staining produced (25). However, it does provide a standard, and 267 
observable, level to which the finding of this study can be compared to the findings of other 268 
studies.  269 
   After polymerization shrinkage (in the case of micro filler and nano filler hybrids) and 270 
secondary caries, plaque accumulation and color stability are most often mentioned as major 271 
problems in tooth-colored restorations. Since chlorhexidine is often prescribed for patients 272 
with both an elevated caries risk and persistent periodontal problems, the possibility or 273 
probability of staining takes on a certain level of importance.  274 
   Stober et al. (2001) also offer a review of 6 studies evaluating the level of overall color 275 
change (ΔE*) that can be detected by the human eye (25). Their conclusion, which is 276 
consistent with Fay et al. (1999), Abu-Bakr et al. (2000), and Lee & Powers (2004), is that a 277 
value of greater that 3.3 is visible to the human eye and must be considered unacceptable (26-278 
28). 279 
   Based on these parameters, the results of the present study show that contact with saliva and 280 
tea alone was enough to cause clinically unacceptable color changes on enamel, dentin, 281 
micro-filler, nano-filler and ceramic restorative materials. This finding was unexpected and is 282 
in contrast to findings of other studies that found significantly less staining when specimens 283 
are subjected to saliva, water and tea than when CHX is added to the submersion protocol (29, 284 
30). However Carpenter et al. (2005) also found greater staining on their specimens 285 
(hydroxyapatite discs pre-treated with parotid saliva to form an acquired pellicle) when 286 
exposed to tea alone than when exposed to CHX and tea together (31). Thus, there is no 287 
consensus concerning this issue. Methodological aspects in terms of substrate to be stained, 288 
pellicle formation and teas used and immersion protocols may cause differences in the 289 
outcomes.  290 
   The second null hypothesis, that Parodentosan will stain, as measured by overall color 291 
change, as heavily as an equivalently dosed non-additive CHX solution was confirmed on a 292 
statistical level on all test substrates except the micro-filler. There was, however, a displayed 293 
tendency to lesser overall color change on the other 2 restorative materials as well as the 294 
enamel and dentin specimens. Both the micro-filler and ceramic restorative materials also 295 
displayed statistically less darkening (ΔL*).  296 
   This tendency toward lesser staining/darkening by essential oil compounds has also been 297 
observed in at least two comparative trials between CHX and Listerine (32, 33). The additives 298 
in Parodentosan, menthol, myrrh and sage, are similar to those found in Listerine, where they 299 
have been proven to be clinically effective anti-gingivitis and, though to a lesser degree, anti-300 
plaque agents that do not promote extrinsic tooth stain (33, 34). So while their inclusion in 301 
Parodentosan inactivated the CHX to a significant degree, as shown in the biofilm 302 
experiment, the mouth rinse still displays a statistical significance when compare to the water 303 
control in reducing biofilm growth.  304 
   In general, it must be remembered that the staining protocol, as explained in the Methods 305 
section, was designed to provide maximum staining potential in an in vivo setting.  As such, it 306 
has a restricted applicability to a clinical situation where different types of tea (in different 307 
concentrations, temperatures, possibly the presence of milk) was well as other dietary 308 
chromogens and the influence of tooth brushing and tooth pastes all play a role in the 309 
accumulation of extrinsic stains (19, 27). However, such protocols do allow comparisons 310 
between test solutions and test substrates, and point out staining tendencies that might warrant 311 
further investigation. 312 
   An unexpected observation was that the 0.05% non-additive CHX solution produced both 313 
overall color change and darkening to the same order of magnitude as the 0.2% solution. 314 
CHX has been shown over the years and in many studies to be dose dependent (35-37). 315 
However, a careful analysis of previous dose and staining trials revealed one study that 316 
provided a similar result, whereby a 0.1% CHX solution stained significantly more than a 317 
0.2% solution (19). The authors of this study did not address this result in their discussion of 318 
their findings. Here, too, the factors behind this result are not clear. Possible explanations 319 
include mechanisms of competitive binding to the pellicle, saturation of receptors or changes 320 
in valency of the dicationic molecule. Further research is needed to clarify this issue. 321 
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 335 
Conclusions 336 
   The 0.05% chlorhexidine digluconate solution containing EO and alcohol components 337 
(Parodentosan) under investigation showed a significant reduction of biofilm formation. 338 
However, this action was less pronounced than the pure CHX controls with or without 339 
alcohol. The test solution displayed significantly less staining on a micro-filler composite 340 
restorative material than either a 0.05% or 0.2% non-additive CHX solution. It caused, 341 
however, an overall color change on enamel, dentin, a nano-filler composite and ceramic 342 
restorative materials. While not statistically significant, it was slightly less pronounced than 343 
the staining caused by the non-additive CHX solutions tested. In general, the restorative 344 
materials displayed significantly less color change and loss of luminosity after having been 345 
bathed in saliva, CHX and tea than did the enamel and dentin substrates tested under the same 346 
conditions. 347 
 348 
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Table 1  Test and control solutions 
Type Brand name Manufacturer 
CHX 0.05%  Parodentosan Tentan AG,  
with sage, menthol, myrrhe   Ramlinsburg, Switzerland 
and 15 Vol.% ethanol 
CHX 0.05%  (produced in-house) Kantonsapotheke 
non-additive                                                                                      Zurich, Switzerland 
CHX 0.2%  (produced in-house)                         Kantonsapotheke 
non-additive                                                                                       Zurich, Switzerland 
Deionized H2O (produced in-house)                         Kantonsapotheke 
                                                                                                           Zurich, Switzerland 
Tea Marks and Spencer extra strong      Marks and Spencer 
                                                          London, UK 
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Table 2  Study specimens 
Type Brand name Manufacturer 
 
Enamel ------- ------- 
Dentin ------- ------- 
Micro filler Tetric A2 Ivoclar, Schaan, Liechtenstein 
Nano filler Filtek Supreme XT A2B 3M ESPE, Seefeld, Germany 
Glass ceramic Empress CAD A2 Ivoclar, Schaan, Liechtenstein 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
 424 
 425 
 426 
 427 
 428 
 429 
.
1
10
100
1000
10000
100000
1000000
1E7
1E8
1E9
w
at
er
co
nt
ro
l
0.
2%
 C
H
X
0.
2%
 C
H
X
15
%
 e
th
an
ol
0.
05
%
 C
H
X
15
%
 e
th
an
ol
P
ar
ad
en
to
sa
n
 430 
 431 
 432 
 433 
 434 
 435 
Fig. 1.  Colony-forming units (CFUs) after exposure to test substances 436 
            * indicates statistical significance at p<0.05  437 
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Table 3   Mean Changes in luminosity, color, chroma and hue (± one standard deviation) 
               Identical upper case letters (to be read horizontally) indicate a significant difference 
         Water   CHX 0.05     CHX 0.2 Paradentosan 
Enamel ∆ L   -8.5 ± 3.5  -10.1 ± 0.7 AB    -8.9 ± 2.7 A   -8.6 ± 2.2 B 
 ∆ a    6.1 ± 1.9     6.8 ± 0.8     7.5 ± 1.1    6.7 ± 1.0 
 ∆ b  12.6 ± 3.6   14.4 ± 1.2   15.4 ± 1.8  13.2 ± 1.1 
 ∆ E  16.5 ± 4.8   18.8 ± 1.1   19.5 ± 2.3  17.3 ± 2.2 
 ∆ C  14.0 ± 3.9 A   15.9 ± 1.4   18.0 ± 2.1 A  14.8 ± 1.4 
 ∆ H  23.4 ± 6.8   26.6 ± 1.6   28.1 ± 3.4  24.5 ± 3.1 
      
Dentin ∆ L -11.3 ± 4.0  -15.0± 2.9  -14.0 ± 2.8 -10.9 ± 3.1 
 ∆ a    7.1 ± 1.5 AB    9.8 ± 1.5 A     9.6 ± 1.4 B    8.5 ± 1.9 
 ∆ b  15.0 ± 3.0  16.9 ± 3.3   17.0 ± 2.7  13.9 ± 4.5 
 ∆ E  20.5 ± 3.1  24.7 ± 4.0   24.2 ± 3.1  19.8 ± 5.1 
 ∆ C  16.7 ± 2.8  19.6 ± 3.0   19.6 ± 2.5  16.4 ± 4.4 
 ∆ H  29.0 ± 4.4 A  35.0 ± 5.8 B   34.2 ± 4.3 C    7.5 ± 2.9 ABC 
      
Composite  ∆ L   -3.0 ± 1.7 AB   -5.8 ± 1.0 A    -5.6 ± 0.5 B   -4.0 ± 2.2 
(micro filler) ∆ a    1.7 ± 0.9 AB    3.7 ± 0.4 A     3.6 ± 0.4 B    2.5 ± 1.6 
 ∆ b    3.9 ± 1.1 AB    7.9 ± 0.8 A     8.3 ± 0.6 B    5.8 ± 1.6 B 
 ∆ E    5.2 ± 2.0 AB  10.5 ± 1.1 AC   10.6 ± 0.7 BD    7.5 ± 2.0 CD 
 ∆ C    4.2 ± 1.4 AB    8.7 ± 0.8 A     9.0 ± 0.7 B    6.3 ± 2.1 A 
 ∆ H    7.4 ± 2.9 AB  14.8 ± 1.6 AC   15.0 ± 1.10 BD  10.6 ± 4.2 CD 
      
Composite  ∆ L   -3.0 ± 0.9 ABC   -5.6 ± 0.7 A    -5.3 ±0.8 B   -4.3 ± 1.6 C 
(nano filler) ∆ a    1.8 ± 0.5 ABC    3.6 ± 0.6 A     3.6 ± 0.6 B    2.9 ± 1.1 C 
 ∆ b    3.4 ± 0.8 AB    7.4 ± 0.9 A     7.4 ± 0.8 B    5.7 ± 1.1 B 
 ∆ E    4.9 ± 1.2 ABC    9.9 ± 1.2 A     9.8 ± 1.1 B    7.9 ± 2.1 C 
 ∆ C    3.9 ± 0.9 AB    8.2 ± 0.9 A     8.3 ± 0.9 B    6.4 ± 1.5 A 
 ∆ H    6.9 ± 1.7 ABC  14.0 ± 1.6 A   13.9 ± 1.5 B  11.2 ± 3.5 C 
      
Ceramic ∆ L   -2.8 ± 2.0 AB   -5.5 ± 0.8 A    -4.9 ± 0.7 B   -4.6 ± 1.6 
 ∆ a    1.9 ± 1.0 ABC    3.7 ± 0.8 A     3.5 ± 0.5 B    3.5 ± 0.6 C 
 ∆ b    3.1 ± 1.2 ABC    6.7 ± 1.2 A     6.3 ± 1.4 B    6.0 ± 0.5 C 
 ∆ E    4.9 ± 1.2 ABC    9.4 ± 1.5 A     8.8 ± 1.5 B    8.4 ± 0.8 C 
 ∆ C    3.6 ± 1.5 ABC    7.6 ± 1.4 A     7.2 ± 1.5 B    6.9 ± 0.6 C 
 ∆ H    6.6 ± 3.4 ABC  13.4 ± 2.2 A   12.4 ± 2.1 B  11.9 ± 1.2 C 
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